We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Proposes Recommending Celgene’s Revlimid for Bone Marrow Disorder
NICE Proposes Recommending Celgene’s Revlimid for Bone Marrow Disorder
In an about face, a UK healthcare cost watchdog is now recommending coverage of Celgene’s blockbuster cancer drug Revlimid, persuaded by the drugmaker’s proposed payment scheme.